📣 Biotech Stock News 03/26 @ Open
$KOD 60% Positive results for Zenkuda in GLOW2
$LNAI 59% Acquiring BBB Delivery Platform
$BLRX 9% Phase 1/2a Study of GLIX1
$OTLK 3% Closing of $5.0 Million Offering
$ABBV 1% Scientific Differentiation at AMWC
$ABBV 1% New Age of Hyaluronic Acid Injectables
$KMDA 1% FDA Approval of Plasma Collection Center
$HOOK 1% Completion of Sale of Oncology Assets
$NBIX 1% Expert Consensus for Tardive Dyskinesia
$ACHV 0% Cytisinicline's receptor selectivity study
$VKTX 0% Completion of Enrollment in VK2735 Trial
$PLUR -1% Additional Investment at 30% Premium
$NVCR -1% Positive results from PANOVA-4 trial
$RYTM -2% Positive CHMP Opinion for IMCIVREE
$NERV -2% Data from Roluperidone and Olanzapine
$PHGE -3% Launches Security Subsidiary in Israel
$IBRX -4% Statistical Power in NMIBC Trial
$CORT -5% FDA Approves Lifyorli Plus Nab-Paclitaxel
$ORMP -5% Closes on Strategic Partnership
$TNXP -7% First Participant Dosed in TNX-1900 Study
$CUE -8% Host Virtual R&D Day Event
$EDSA -9% Advances Vitiligo Program Enrollment
$DNLI -9% FDA Approval of AVLAYAH for Hunter Syndrome
$ALZN -22% Positive data from Phase II trial
$WVE -54% Positive Phase 1 Data for WVE-007
See image below for details. 👇
📈 2 Big Movers, 2 Suspected Movers to watch into Q1 close!
•
$KOD → Ph3 DR readout (anti-VEGF, high efficacy bar set by Eylea/Lucentis)
•
$PEPG → Ph2 DM1 data (early-stage gene therapy, differentiated approach)
•
$ANRO → Ph2 schizophrenia (CNS small molecule, targeting cognitive impairment, still a large unmet need)
•
$INSM → Ph2b HS (DPP1 small molecule inhibitor vs biologics like TNF/IL-17)
What else are you watching into Q1 close? 👇